Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00632463 · ClinicalTrials.gov registry record · Phase 2

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

A Phase 2 study of Lower Respiratory Tract Infection and Upper Respiratory Tract Infection, sponsored by ADMA Biologics.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target
19
Study locations

NCT00632463 is a Phase 2 study of Lower Respiratory Tract Infection and Upper Respiratory Tract Infection that has completed, run by ADMA Biologics. The registered enrollment target is 21 participants, below the 1,463-participant average among 3 other Lower Respiratory Tract Infection trials with a reported enrollment target (99% lower). The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00632463, a Phase 2 study of Lower Respiratory Tract Infection and Upper Respiratory Tract Infection, has completed, sponsored by ADMA Biologics.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target
19
Study locations

Study Summary

RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being infected with RSV in the upper respiratory tract.

Conditions Studied

Lower Respiratory Tract Infection Upper Respiratory Tract Infection

Interventions

  • BIOLOGICAL RI-001

Study Locations (19)

New York

  • Schneider Children's Hospital - New Hyde Park
  • University of Rochester Medical Center - Rochester

Texas

  • Children's Medical Center of Dallas - Dallas
  • Cook Children's Medical Center - Fort Worth

Washington

  • Seattle Children's Hospital and Regional Medical Center - Seattle
  • Fred Hutchinson Cancer Research Center - Seattle

Quebec

  • Hopital Maisonneuve Rosemont - Montreal
  • Hopital Sainte Justine - Montreal

California

  • University of California San Francisco - San Francisco

Colorado

  • University of Colorado Health Sciences Center - Aurora

District of Columbia

  • Children's National Medical Center - Washington D.C.

Florida

  • All Children's Hospital - St. Petersburg

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2008-02
Est. Completion 2010-05
Phase Phase 2

Sponsor

ADMA Biologics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00632463

The ClinicalTrials.gov registry entry for NCT00632463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,463-participant average among 3 other Lower Respiratory Tract Infection trials with a reported enrollment target (99% lower). The listed sponsor is ADMA Biologics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lower Respiratory Tract Infection appearing as the primary indexed condition, and to 1 intervention - of which RI-001 is the first listed.

NCT00632463 reports 19 study locations spanning 15 distinct geographic areas - top geographies include New York, Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT00632463 about?

NCT00632463 is a clinical study titled "RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness". RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being in...

What is the current status of trial NCT00632463?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-02. Estimated completion is 2010-05.

What conditions does trial NCT00632463 study?

This clinical trial studies the following conditions: Lower Respiratory Tract Infection, Upper Respiratory Tract Infection.

What interventions are being tested in trial NCT00632463?

The interventions under investigation include: RI-001 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00632463?

This trial is sponsored by ADMA Biologics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00632463 being conducted?

This trial has 19 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lower Respiratory Tract Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lower Respiratory Tract Infection

All registered trials for this condition

Upper Respiratory Tract Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.